What it means
Biotechnology is expensive and slow. A new therapy may take a decade of laboratory work, trials and regulatory approval, and most candidates fail along the way.
Intellectual property (IP) rights give the successful inventor a period of exclusivity, which is the time in which competitors cannot copy the invention, so the original investment can be recovered. Patents are the main tool.
They can cover new compounds, methods of treatment, manufacturing processes, engineered organisms and diagnostic techniques, provided the invention is new, useful and not obvious. A patent usually lasts around 20 years from the filing date in most countries, though the effective commercial period is shorter because much of that time is spent in development and approval.
Some areas are legally sensitive. Rules differ between countries on whether naturally occurring genes, living organisms or methods of medical treatment can be patented.
Many countries also have separate protections for new plant varieties, and regulators may grant data exclusivity, which protects clinical trial data for a set period. Not everything is patented.
Companies often keep cell lines, culture methods and manufacturing know-how as trade secrets, which have no fixed expiry but are lost if the secret leaks. Employment agreements, confidentiality clauses and careful access control are therefore part of the IP strategy.
For finance teams, IP is often the largest asset of a biotech company. It affects valuation, licensing income, royalty forecasts, impairment testing and the due diligence that investors perform.
Deals frequently include upfront payments, milestone payments and royalties, and the rights granted, the territories covered and the term are central to what the deal is worth. The main risks are litigation, expiry and design-around.
A competitor may challenge a patent, wait for it to expire and launch a generic or biosimilar product, or find a different route to the same result. Companies therefore build portfolios of overlapping rights and plan for the date when exclusivity ends.
In practice
Real-world examples.
Example
A university spin-out develops a new diagnostic test for a rare disease and files a patent covering the test method. It licenses the patent to a larger laboratory in return for an upfront fee of $500,000 and a 6% royalty on sales. Investors value the spin-out largely on the strength of that licence. If the test reaches $4,000,000 of annual sales, the royalty alone would be worth $240,000 a year.
Example
A seed company breeds a drought-tolerant variety of maize and registers plant variety protection. Competitors cannot sell the same variety without a licence. The company charges farmers a technology fee on each bag of seed. Revenue from the fee funds further breeding work.
Example
A contract manufacturer develops a proprietary method for growing cells at scale and decides not to patent it. It treats the method as a trade secret, restricts access to a few staff and requires confidentiality agreements. The method gives the firm a pricing advantage for as long as it stays secret.
Case study
Seen in the real world.
Verdance Therapeutics is a fictional biotech company that spent $60,000,000 over eight years developing a treatment for a rare skin condition. It held a portfolio of patents on the compound, the formulation and the manufacturing process. Investors judged the strength of that portfolio before putting in a new round of funding.
In this illustrative story, a larger pharmaceutical company offered a licence with a $20,000,000 upfront payment, milestone payments and a royalty. Verdance's lawyers made sure the licence defined the territories, the field of use and who would defend the patents. The deal funded the final trials while keeping the company's ownership of the underlying IP.
The finance team recorded the upfront payment as deferred income and recognised it over the period of the agreement, in line with its auditors' advice. The board also created a calendar of patent renewal dates so that no right would lapse through an oversight.
Watch out
Common mistakes.
- Publishing research results before filing a patent. Early disclosure can destroy novelty and block protection in many countries.
- Assuming a patent in one country protects the invention worldwide. Patents are national or regional, so protection must be sought where it is needed.
- Ignoring who owns the IP. Without clear contracts, universities, employers or collaborators may have a claim on the invention.
Questions
People also ask.
How long does biotechnology patent protection last?
Typically around 20 years from filing, though some countries offer extensions for products that need long regulatory approval.
Can a gene be patented?
It depends on the country and the type of claim, as many systems allow patents on engineered or synthetic materials but restrict claims on naturally occurring genes.
How is biotech IP valued?
Analysts usually estimate future cash flows from the product, adjust for the chance of regulatory success and the remaining protection period, and discount them to a present value.
From the founder's library
Take it further with the book.
Build your financial confidence beyond this definition. Shihan's full-length guide, Accounting Fundamentals, takes the same plain-English approach and turns it into a complete, practical playbook for non-finance managers, business owners and students - with chapter-end quiz answers and presentation slides included.
25% off with code MMHQ25, applied at checkout. Priced in USD - checkout may show the equivalent in your local currency.
View the book and save 25%Related